Indications (United States)

The BAROSTIM NEO® System is indicated for the improvement of symptoms of heart failure—quality of life, six-minute hall walk and functional status—for patients who remain symptomatic despite treatment with guideline-directed medical therapy with:

  • NYHA Class III or Class II (who had a recent history of Class III)
  • Left ventricular ejection fraction ≤ 35%
  • NT-proBNP < 1600 pg/ml

Excluding patients indicated for Cardiac Resynchronization Therapy (CRT) according to AHA/ACC/ESC guidelines.

Contact Me